ABVC BioPharma, Inc. (ABVC) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2025. ABVC BioPharma, Inc. is an early-stage clinical biopharmaceutical company focused on developing botanical drugs and medical devices for Central Nervous System (CNS), oncology/hematology, and ophthalmology indications. The company operates through wholly-owned subsidiaries including BioKey (CDMO services), BioLite (drug development), and AiBtl (CNS drug licensing). The company is listed on the Nasdaq Capital Market under the symbol "ABVC."
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $509,589 |
| Net Loss | $(8,376,959) | $(5,259,037) |
| Operating Expenses | $7,151,259 | $5,214,068 |
| Stock-Based Compensation | $4,142,816 | $2,773,460 |
| Cash and Cash Equivalents | $681,480 | $248,382 |
| Working Capital Deficit | $(3,662,633) | $(4,377,646) |
| Total Liabilities | $7,764,723 | $6,815,948 |
| Stockholders' Equity | $13,297,480 | $723,959 |
Note: The company reported $0 revenue for 2025 after restating previously recognized licensing revenue of approximately $796,000 due to improper revenue recognition practices.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $0 in 2025 from $509,589 in 2024. This was primarily due to a restatement reversing $795,950 of licensing revenue recognized in Q3 2025 from related parties (OncoX and ForSeeCon) because the funds did not meet contractual fundraising covenants.
- Increased Net Loss: Net loss increased by 59% to $8.4 million, driven by higher operating expenses (up 37%) and a $803,008 impairment loss on an equity investment in BioHopeKing Corporation.
- Equity Increase: Stockholders' equity increased significantly from $724k to $13.3M, primarily due to private placements raising $3.3M, warrant exercises, and the issuance of stock for land acquisitions.
- Debt Repayment: The company fully converted or repaid its significant "Lind Notes" convertible debt obligations during 2025, reducing interest expense compared to 2024.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Pipeline:
- CNS Pipeline: ABV-1504 (MDD) Phase II completed; ABV-1505 (ADHD) Phase II Part II interim analysis submitted to FDA.
- Oncology Pipeline: ABV-1703 (Pancreatic Cancer) and ABV-1519 (Lung Cancer) Phase II trials expected to begin in 2026.
- Medical Device: ABV-1701 (Vitargus) Phase II study ongoing in Australia and Thailand.
Material Risks:
- Going Concern: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and working capital deficits. Continued operations depend on raising additional capital.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding revenue recognition, share-based payments, and complex transactions, leading to restatements of 2023 and Q3 2025 financials.
- Nasdaq Compliance: The company previously faced delisting risks regarding minimum bid price and stockholders' equity but regained compliance in May 2025.
- Related Party Transactions: Significant reliance on related parties for funding, licensing, and land acquisitions, which introduces valuation and conflict of interest risks.
Unusual Items:
- Restatement: Q3 2025 financials were restated to reverse $795,950 in revenue and adjust land acquisition costs by $798,486.
- Land Acquisition: Acquired land in Taoyuan City, Taiwan, from a director (Shuling Jiang) via stock and warrant issuance, valued at $4.66M based on equity fair value rather than appraisal.
Investor Verification Checklist
- Restatement Details: Verify the specific accounting adjustments made to the Q3 2025 and 2023 financial statements regarding revenue recognition and asset valuation.
- Liquidity Runway: Assess the company's cash burn rate ($2.99M operating cash outflow in 2025) against current cash balances ($681k) to determine the immediate need for capital raises.
- Related Party Valuations: Scrutinize the valuation methodology used for the land acquisition from Director Shuling Jiang and the licensing agreements with OncoX and ForSeeCon.
- Internal Control Remediation: Review the specific steps management is taking to remediate the identified material weaknesses in internal controls.
- Clinical Trial Timelines: Confirm the status and funding for the Phase II trials scheduled to begin in 2026, given the current lack of revenue.